These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 3426872)

  • 61. [The role of immunization against bacterial enteric infections (author's transl)].
    Rey M
    Med Trop (Mars); 1979; 39(4):457-62. PubMed ID: 537492
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Reactogenicity and immunological effectiveness of a chemical sorbed typhoid vaccine in combination with choleragen-anatoxin administered subcutaneously by jet injector].
    Gapochko KG; Emel'ianova OV; Konovalov SI; Mokrousov VB; Ttiova TS
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Feb; (2):95-7. PubMed ID: 6711201
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The human humoral immune response to Salmonella typhi Ty21a.
    Forrest BD; LaBrooy JT; Beyer L; Dearlove CE; Shearman DJ
    J Infect Dis; 1991 Feb; 163(2):336-45. PubMed ID: 1988518
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Serologic studies following cholera vaccination].
    Ambrosch F; Hirschl A; Stanek G; Stemberger H; Wiedermann G; Wustinger E
    MMW Munch Med Wochenschr; 1983 Mar; 125(11):213-5. PubMed ID: 6405216
    [No Abstract]   [Full Text] [Related]  

  • 66. Evolution of the typhoid immunity along one year after intradermal vaccination.
    Dimache G; Croitoru M; Ciordaş C; Velea V
    Arch Roum Pathol Exp Microbiol; 1986; 45(2):147-52. PubMed ID: 3800632
    [No Abstract]   [Full Text] [Related]  

  • 67. Cell-bound haemagglutinin (CHA) of V. cholerae 01 as protective antigen.
    Chaicumpa W; Boonthum A; Kalumbaheti T; Tapchaisri P
    Southeast Asian J Trop Med Public Health; 1984 Sep; 15(3):407-13. PubMed ID: 6523176
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Serologic response in man to cholera vaccine].
    Di Tommaso I
    Ann Sclavo; 1973; 15(4):445-52. PubMed ID: 4788453
    [No Abstract]   [Full Text] [Related]  

  • 69. Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.
    Attridge SR; Rowley D
    J Infect Dis; 1983 Nov; 148(5):931-9. PubMed ID: 6195273
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Vaccination against cholera: what prospects?].
    Pierre P; Lucas G; Vaerman JP
    Ann Soc Belg Med Trop; 1988 Jun; 68(2):83-93. PubMed ID: 3071278
    [No Abstract]   [Full Text] [Related]  

  • 71. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.
    Kollaritsch H; Furer E; Herzog C; Wiedermann G; Que JU; Cryz SJ
    Infect Immun; 1996 Apr; 64(4):1454-7. PubMed ID: 8606118
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Persistence in the mouse gut as an important factor in oral immunogenicity of strains of V. cholerae.
    Bloom L; Rowley D
    Aust J Exp Biol Med Sci; 1979 Jun; 57(3):325-33. PubMed ID: 533484
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Obtaining and Characteristic of Antibodies to Vibrio cholerae Protective Antigens Conjugated with Gold Nanoparticles.
    Dykman LA; Volokh OA; Gromova OV; Durakova OS; Vorobeva SA; Kireev MN; Livanova LF; Nikiforov AK; Shchyogolev SY; Kutyrev VV
    Dokl Biochem Biophys; 2020 Jan; 490(1):19-21. PubMed ID: 32342306
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines.
    D'Amelio R; Tagliabue A; Nencioni L; Di Addario A; Villa L; Manganaro M; Boraschi D; Le Moli S; Nisini R; Matricardi PM
    Infect Immun; 1988 Oct; 56(10):2731-5. PubMed ID: 3417354
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genomics of immune response to typhoid and cholera vaccines.
    Majumder PP
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1671):. PubMed ID: 25964454
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [A new vaccinating antigenic fraction obtained from "Vibrio cholerae" II. Biological properties of the Ch1+2 fraction compared with the bacterial vaccine (author's transl)].
    Dobin A; Wiart J
    Ann Microbiol (Paris); 1975 Jan; 126(1):45-56. PubMed ID: 811147
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103.
    Ketley JM; Kaper JB; Herrington DA; Losonsky G; Levine MM
    Infect Immun; 1990 May; 58(5):1481-4. PubMed ID: 2323828
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Brucella antibodies and oral cholera vaccination.
    Begue RE; Guillen A; Meza R
    Lancet; 1995 Jul; 346(8967):115-6. PubMed ID: 7603186
    [No Abstract]   [Full Text] [Related]  

  • 79. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination].
    Sumarokov AA; Ivanov NR; Lelikov VL; Dzhaparidze MN; Karaeva LT
    Zh Mikrobiol Epidemiol Immunobiol; 1978; (12):87-92. PubMed ID: 371293
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The suppressive effect of circulating specific antibody on the response to oral immunisation with Vibrio cholerae.
    Horsfall DJ; Brown MA; Rowley D
    Aust J Exp Biol Med Sci; 1979 Jun; 57(3):271-8. PubMed ID: 533481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.